These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33350511)

  • 1. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
    Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
    De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
    J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
    Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
    J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
    Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
    Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
    Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
    Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
    Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
    EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
    De Ridder T; Reddell P; Jones P; Brown G; Campbell J
    Front Vet Sci; 2021; 8():764800. PubMed ID: 34977208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of intralesional triamcinolone administration for treatment of mast cell tumors in dogs: 23 cases (2005-2011).
    Case A; Burgess K
    J Am Vet Med Assoc; 2018 Jan; 252(1):84-91. PubMed ID: 29244608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
    Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
    Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of scar revision after inadequate primary excision of cutaneous mast cell tumors in 85 dogs (2000-2013).
    Karbe GT; Davis E; Runge JJ; Brown DC; Holt DE
    Vet Surg; 2021 May; 50(4):807-815. PubMed ID: 33666268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
    Gasser K
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2022 Jun; 50(3):225-231. PubMed ID: 35790169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: A prospective 2-year-long study.
    Milovancev M; Townsend KL; Tuohy JL; Gorman E; Bracha S; Curran KM; Russell DS
    Vet Surg; 2020 Jan; 49(1):96-105. PubMed ID: 31044443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications.
    Iodence AE; Wallace ML; Grimes JA; Schmiedt CW
    J Am Vet Med Assoc; 2021 Dec; 260(S1):S88-S95. PubMed ID: 34914619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
    De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
    Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast cell tumour destruction in dogs by hypotonic solution.
    Grier RL; Di Guardo G; Myers R; Merkley DF
    J Small Anim Pract; 1995 Sep; 36(9):385-8. PubMed ID: 8583766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012).
    Pratschke KM; Atherton MJ; Sillito JA; Lamm CG
    J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs.
    Itoh T; Kojimoto A; Uchida K; Chambers J; Shii H
    J Vet Med Sci; 2021 Feb; 83(2):230-233. PubMed ID: 33342962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs.
    Spugnini EP; Vincenzi B; Citro G; Dotsinsky I; Mudrov T; Baldi A
    J Vet Intern Med; 2011; 25(2):407-11. PubMed ID: 21382075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008).
    Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M
    J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002).
    Séguin B; Besancon MF; McCallan JL; Dewe LL; Tenwolde MC; Wong EK; Kent MS
    J Vet Intern Med; 2006; 20(4):933-40. PubMed ID: 16955819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.